Treats hypertension. ANDA 204058, held by InvaGen Pharmaceuticals. Hydrochlorothiazide; Lisinopril.
As of Nov 21, 2026, ANDA 204058 (Lisinopril and Hydrochlorothiazide), held by InvaGen Pharmaceuticals, was first approved by FDA on May 23, 2017, with 2 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Lisinopril and hydrochlorothiazide tablets, USP are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including lisinopril and hydrochlorothiazide. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake.
| Date | Submission | Status | Documents |
|---|---|---|---|
| May 23, 2017 | Original application | Approved | None posted |
| Lisinopril and Hydrochlorothiazide12.5MG;10MG · tablet;oral | Hydrochlorothiazide; Lisinopril | Rx |
| Lisinopril and Hydrochlorothiazide12.5MG;20MG · tablet;oral | Hydrochlorothiazide; Lisinopril | Rx |
| Lisinopril and Hydrochlorothiazide25MG;20MG · tablet;oral | Hydrochlorothiazide; Lisinopril | Rx |
| May 31, 2024 | Supplement 11Labeling · Standard review | Approved | None posted |
| Aug 7, 2020 | Supplement 4Labeling · Standard review | Approved | None posted |
| May 23, 2017 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters